ReviewFrontiers in oncology2026
Glycosylated RNAs: discovery and implications in cancer biology.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Glycosylation of Extracellular Vesicles: Analytical and Translational Insights into Biomarker Discovery and Regenerative Medicine.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glycosylated RNAs (glycoRNAs) are a newly discovered class of biomolecules that challenge the long-standing paradigm that glycosylation occurs exclusively on proteins and lipids. Early studies indicate that glycoRNAs are broadly distributed across cell types and can be detected at the cell surface as well as in other cellular compartments. Emerging evidence suggests that glycoRNAs may participate in processes such as intercellular communication and immune regulation, but their context-dependent functions in physiology and disease, including cancer, are only beginning to be elucidated. Recent advances in detection techniques have enabled more comprehensive profiling of glycoRNAs and their associated cell-surface RNA-binding proteins, providing initial links between glycoRNA patterns, tumor aggressiveness, immune checkpoint regulation and extracellular vesicle-mediated signaling. However, many of these connections remain correlative or are inferred by analogy to protein and lipid glycosylation. In this review, we summarize current knowledge of glycoRNA biosynthesis, cell-surface display and detection methods, with a particular focus on emerging observations in cancer-related contexts. We also discuss the potential of glycoRNAs as biomarkers and therapeutic targets, while highlighting key unanswered questions regarding their biosynthetic pathways, structural diversity and mechanistic roles. Addressing these challenges with integrated omics and spatial approaches will be essential for defining glycoRNA biology and evaluating their feasibility as tools for precision oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.